GlassScriptPhysician profile
Krishnamohan R Basarakodu
NPI 1235248477
$11,740.83
in general payments reported to CMS, 2019-2025
62 companies · $2,374 in 2025
The $2,374 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $391 · 2021: $520 · 2022: $2,511 · 2023: $2,323 · 2024: $1,945 · 2025: $2,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,542 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,542.17 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $939.51 | 2019-2025 | |
| Pfizer INC. | $780.00 | 2019-2025 | |
| Janssen Biotech, INC. | $770.19 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $763.56 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $668.10 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $556.70 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Lilly USA, LLC | $546.92 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $540.52 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $524.13 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $430.53 | 2019-2025 | Tecentriq, Polivy, Columvi |
| Amgen INC. | $383.54 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Regeneron Healthcare Solutions, INC. | $331.53 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $321.97 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Ipsen Biopharmaceuticals, INC | $295.72 | 2019-2025 | Onivyde, Somatuline Depot |
| Seagen INC. | $276.66 | 2019-2023 | Adcetris, Padcev, Tukysa |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnamohan Basarakodu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.